Fred Hutch News Service

At Fred Hutch, our diverse teams of leading scientists and dedicated humanitarians collaborate to tackle cancer, HIV/AIDS, and other health challenges. Among our researchers are three Nobel Prize winners, all driven by an unwavering commitment to advancing health knowledge and spreading hope globally. Our collective efforts focus on finding innovative methods for early cancer detection, when treatment success is greatest; creating effective therapies with reduced side effects; and exploring strategies to prevent cancer development altogether.

Trade/B2B

English

Research Company/Group

Outlet metrics

Domain Authority

Ranking

Global

#125543

United States

#34220

Health/Health Conditions and Concerns

#65

Traffic sources

Monthly visitors

Articles

New horizons in infectious disease treatment and prevention in immunocompromised patients

5 days ago | fredhutch.org | Sabrina Richards

Infectious disease specialist Camille Kotton, MD, clinical director of Massachusetts General Hospital’s Transplant Infectious Disease and Immunocompromised Host Program, discussed novel vaccines and monoclonal antibodies for respiratory viruses, including respiratory syncytial virus, or RSV. This virus causes a lot of disease in immunocompromised people, but those younger than 60 are not currently included in the Center for Disease Control’s RSV vaccination guidelines.
Women’s Health Initiative: Research that keeps on giving | Fred Hutchinson Cancer Center

1 month ago | fredhutch.org

The Women's Health Initiative — which houses its data center at Fred Hutch — is the largest women’s health study ever conducted on the planet, recruiting more than 161,000 women ages 50 to 79 and engaging more than 5,000 scientists from the U.S. and beyond.
Dr. Peter Gilbert receives Marvin Zelen Leadership Award in Statistical Science

1 month ago | fredhutch.org | Sabrina Richards

After receiving his PhD in biostatistics at the University of Washington, Gilbert moved to Zelen’s department at Harvard, focusing on analyzing and designing clinical trials to test treatments for HIV. From the beginning, he integrated students into his research, a theme that would continue throughout his career. In 2001, Gilbert’s doctoral mentor, UW biostatistician Steven Self, PhD, enticed him back to Seattle to support the rapidly expanding statistical science developments at Fred Hutch.
Fred Hutch study finds genetic driver of drug resistance in small cell lung cancer

1 month ago | fredhutch.org | John Higgins

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes hopes. “What is seen in the clinic is often quite remarkable responses to chemotherapy initially, but these are just transient responses and tumors come back,” said David MacPherson, PhD, a Fred Hutch Cancer Center scientist who specializes in small cell lung cancer.
A swollen lymph node leads to a diagnosis of throat cancer

1 month ago | fredhutch.org | Bonnie Rochman

In 2023, Jack David was on his family’s annual trip to Priest Lake, Idaho, when he woke up in the middle of that vacation and felt a swollen lymph node. He made a few jokes about what it could be, then saw his doctor when he returned home to Seattle, which led to a referral to an otolaryngologist. David, 49, was given a prescription for antibiotics, but the node didn’t subside. Results from a biopsy appeared normal, but the node still didn’t disappear.
RNA “typos” can highlight leukemia cells for immune attack

2 months ago | fredhutch.org | Sabrina Richards

Bradley and Abdel-Wahab have a long-standing collaboration working out how mutations in certain splicing factor genes drive leukemia, with an eye toward leveraging the knowledge to develop new treatments. “We were wondering, could cancers with mutations in the splicing machineries just on their own generate novel proteins that could be really amazing therapeutic targets — if we could figure out what those novel proteins are and what the immune cells that recognize them are,” Abdel-Wahab said.
Managing mountains of genomic data

2 months ago | fredhutch.org | John Higgins

From the earliest days of the pandemic that shocked the world in 2020, researchers at Fred Hutch Cancer Center tracked the rapid evolution and spread of the virus that causes COVID-19 by studying how its genomic sequence — the order of its genetic building blocks — changed over time.
Rewriting the story about the molecules that turn genes on and off

2 months ago | fredhutch.org | John Higgins

Some things just go together like “rock and roll” and “fish and chips” or, in molecular biology, “transcription factors” and the “nearby genes they regulate.” The standard, simplified story goes like this: transcription factors are molecular workers that scan DNA strands and bind to specific sequences close to the genes they either turn on or off.
Multiple myeloma is treatable, not curable. Is that set to change?

2 months ago | fredhutch.org | Bonnie Rochman

At age 89, Cal Crow plays water volleyball three days a week, then chases that with a 1,000-foot swim; on his off days, he logs at least a mile around his neighborhood — and that’s with a cancer diagnosis. In 2019, Crow was having trouble hearing and went to see a physician who misdiagnosed him. He sought a second opinion at Fred Hutch Cancer Center, where a full body scan revealed that Crow had multiple myeloma. “I didn’t know what that was,” said Crow.
Cell biologist and former Fred Hutch division leader Dr. Jonathan Cooper retires

Mar 26, 2025 | fredhutch.org | John Higgins

After 40 years at Fred Hutch Cancer Center asking good questions of his own science and the science of his colleagues, cell biologist Jonathan Cooper, PhD has retired from the Basic Sciences Division. He made his name in biology by identifying key components of a complex relay system that enables cells to communicate with each other.